WASHINGTON, D.C. -- In response to the Trump Administration’s announcements of CMS loosening regulations for telehealth in Medicare and FDA empowering states on testing in efforts to counter the COVID-19 pandemic, Adam Brandon, FreedomWorks’ President, commented:

WASHINGTON, D.C. -- In response to the insertion of a provision calling for price controls on vaccines in the congressional coronavirus package, Adam Brandon, FreedomWorks’ President, commented:

WASHINGTON, D.C. -- In response to efforts by Democratic House leadership to tie the reauthorization of the USA PATRIOT Act to the coronavirus spending package, Jason Pye, FreedomWorks’ Vice President of Legislative Affairs, commented:

WASHINGTON, D.C. -- In response to Sen. Chuck Grassley’s (R-Iowa) most recent support for government mandated price controls on prescription drugs, Dan Savickas, FreedomWorks Regulatory Policy Manager, commented:

WASHINGTON, D.C. -- In response to the closing of the comment period on the Center for Medicare and Medicaid Services’ proposal on organ procurement, Dan Savickas, FreedomWorks Foundation Regulatory Policy Manager, commented:

WASHINGTON, D.C. -- In response to the Trump Administration’s recent decision to proceed with a rules change that will initiate much needed organ procurement organization (OPO) reform, Adam Brandon, FreedomWorks’ president, commented:

WASHINGTON, D.C. -- Following the vote in the House of Representatives on Speaker Nancy Pelosi’s (D-Calif.) socialist price control bill, H.R. 3, Adam Brandon, FreedomWorks’ president, commented: